BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 clinical studies for NG2-73, the Company’s lead compound for the treatment of insomnia, were presented today at the SLEEP 2007 Annual Meeting of the Associated Professional Sleep Societies (APSS) in Minneapolis, Minnesota. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the APSS meeting today includes the following:
